Trevena Inc is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands.
| FactSnippet No. 1,660,524 |
14 Facts About Trevena Inc
1.
2.
Trevena Inc was named one of the top 15 US startups of 2008 by Business Week.
| FactSnippet No. 1,660,525 |
3.
In early 2009, Trevena Inc entered into a collaborative agreement with Ligand Pharmaceuticals to identify biased ligands at numerous GPCRs from a large, diverse chemical library.
| FactSnippet No. 1,660,526 |
4.
Later that year, Trevena Inc received a competitively awarded American Recovery and Reinvestment Act Grand Opportunities Grant, spanning two years and funding US$7.
| FactSnippet No. 1,660,527 |
5.
Trevena Inc has disclosed specific interests in the mu Opioid receptor and kappa Opioid receptor.
| FactSnippet No. 1,660,528 |
6.
Trevena Inc raised an additional US$35 million in a B round of venture financing in the summer of 2010.
| FactSnippet No. 1,660,529 |
7.
Trevena Inc's leading drug candidate is Oliceridine, a G protein-biased ligand binding to the mu opioid receptor for the intravenous treatment of acute moderate-to-severe post-operative pain.
| FactSnippet No. 1,660,530 |
8.
In January 2017, Trevena Inc announced that enrollment for its phase III trials, APOLLO-1 and APOLLO-2 are complete.
| FactSnippet No. 1,660,531 |
9.
In November 2018, Trevena Inc received a Complete Response Letter from FDA regarding Oliceridine and the need for additional safety data.
| FactSnippet No. 1,660,532 |
11.
Trevena Inc announced DEA scheduling, Schedule II controlled substance, of oliceridine on October 30,2020.
| FactSnippet No. 1,660,534 |
12.
Trevena Inc's developed TRV027 for acute heart failure, targets the angiotensin receptor utilizing beta-arrestin bias, an approach that has shown numerous beneficial cardiovascular and renal actions in preclinical species.
| FactSnippet No. 1,660,535 |
13.
In May 2016, Trevena Inc announced that the TRV027 phase II trial failed to meet its primary endpoints and they were no longer developing the drug.
| FactSnippet No. 1,660,536 |
14.
Trevena Inc announced it has entered into a collaboration with Imperial College London to evaluate the potential of TRV027, a novel AT1 receptor selective agonist, to treat acute lung injury contributing to acute respiratory distress syndrome in COVID-19 patients.
| FactSnippet No. 1,660,537 |